Biotech firm Oxford Biomedica has been given a multi-million pound boost after one of its key vaccines was given the green light to continue testing.
The Data Safety Monitoring Board has ruled that Trovax, which is undergoing Phase III tests for kidney cancer, can continue the trials without modification.
And this has triggered a milestone payment worth 10m euros (£7.6m) for the company based at the Oxford Science Park which is developing the vaccine in a £350m partnership with pharmaceutical firm Sanofi-Aventis.
Professor Alan Kingsman, chief executive of Oxford BioMedica, said: "The DSMB's recommendation to continue the TRIST study is another important step in the Phase III development of TroVax.
"The trial is on track to complete patient enrolment before the end of this quarter and we anticipate final results in 2009."
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules hereComments are closed on this article